Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer

Nuclear Medicine and Biology

Volumn 40, Issue 8, 2013, Pages 1025-1034

  Richter, Susan ^a   Wuest, Melinda ^a   Krieger, Stephanie S ^b   Rogers, Buck E ^b   Friebe, Matthias ^c   Bergmann, Ralf ^d   Wuest, Frank ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Piramal Enterprises Limited   (India)

^d INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

18F; Bombesin (BBN); Gastrin releasing peptide (GRP) receptor; N succinimidyl 4 18F fluorobenzoate ( 18F SFB); Positron emission tomography (PET); Prostate cancer

Indexed keywords

CALCIUM ION; FLUORINE BOMBESIN 1 F 18; FLUORINE BOMBESIN 2 F 18; FLUORINE BOMBESIN 3 F 18; GASTRIN RELEASING PEPTIDE RECEPTOR; IODINE TYROSINE BOMBESIN I 125; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; RADIOPHARMACEUTICAL AGENT; SUCCINIMIDE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BIOACCUMULATION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; COMPLEX FORMATION; CONJUGATION; CONTROLLED STUDY; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOLECULAR STABILITY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOASSAY; RADIOISOTOPE DECAY; RADIOISOTOPE DISTRIBUTION; RECEPTOR BINDING; TISSUE DISTRIBUTION;

(18)F; BOMBESIN (BBN); GASTRIN-RELEASING PEPTIDE (GRP) RECEPTOR; N-SUCCINIMIDYL-4-[(18)F]FLUOROBENZOATE ([(18)F]SFB); POSITRON EMISSION TOMOGRAPHY (PET); PROSTATE CANCER;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BOMBESIN; CALCIUM; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG STABILITY; FLUORINE RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; MALE; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOCHEMISTRY; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN;

EID: 84886295631     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.07.005     Document Type: Article

References (38)

1. Canadian Cancer Society Canadian Cancer Statistics 2012. Toronto, ON 2012, 7-8.
2. Schröder F.H., Roobol M.J. Prostate cancer epidemic in sight?. Eur Urol 2012, 61(6):1093-1095.
3. http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatefinalrs.htm.
4. Jadvar H. Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging 2009, 8(2):56-64.
5. Jadvar H. FDG PET, in prostate cancer. PET Clin 2009, 4(2):155-161.
6. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR 2012, 199:278-291.
7. Mease R.C. Radionuclide based imaging of prostate cancer. Curr Top Med Chem 2010, 10(16):1600-1616.
8. 4) bombesin by tumor cells. Prostate 1994, 25(1):29-38.
9. Markwalder R., Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59(5):1152-1159.
10. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24(4):389-427.
11. Dorsam R.T., Gutkind J.S. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007, 7(2):79-94.
12. Tokita K., Hocart S.J., Coy D.H., Jensen R.T. Molecular basis of the selectivity of gastrin-releasing peptide receptor for gastrin-releasing peptide. Mol Pharmacol 2002, 61(6):1435-1443.
13. 64Cu-labeled bombesin analogue. Bioconjug Chem 2003, 14(4):756-763.
14. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol 2006, 33(3):371-380.
15. 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjug Chem 2011, 22(8):1729-1735.
16. Mansi R., Wang X., Forrer F., Kneifel S., Tamma M.L., Waser B., et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009, 15(16):5240-5249.
17. Schroeder R.P., van Weerden W.M., Krenning E.P., Bangma C.H., Berndsen S., Grievink-de Ligt C.H., et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2011, 38(7):1257-1266.
18. Abiraj K., Mansi R., Tamma M.L., Forrer F., Cescato R., Reubi J.C., et al. Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours. Chemistry 2010, 16(7):2115-2124.
19. 99mTc](CO)3 bombesin analogues. Nucl Med Biol 2007, 34(1):17-28.
20. Pujatti P.B., Massicano A.V., Mengatti J., de Araújo E.B. Preparation of [In-111]-labeled DTPA-bombesin conjugates at high specific activity and stability: evaluation of labeling parameters and potential stabilizers. Appl Radiat Isot 2012, 70(5):856-863.
21. 177Lu: in vitro and in vivo evaluation. Nucl Med Biol 2009, 36(6):591-603.
22. 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues. Clin Exp Metastasis 2009, 26(2):105-119.
23. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006, 47(3):492-501.
24. 18F radiolabeling of bombesin. Angew Chem Int Ed Engl 2011, 50(47):11117-11120.
25. Schirrmacher E., Wängler B., Cypryk M., Bradtmöller G., Schäfer M., Eisenhut M., et al. Synthesis of p-(di-tert-butyl[(18)F]fluorosilyl)benzaldehyde ([(18)F]SiFA-A) with high specific activity by isotopic exchange: a convenient labeling synthon for the (18)F-labeling of N-amino-oxy derivatized peptides. Bioconjug Chem 2007, 18(6):2085-2089.
26. 18F-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem 2008, 19(9):1871-1879.
27. 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem 2010, 21(10):1864-1871.
28. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med 2011, 52(2):270-278.
29. Yan Y., Chen X. Peptide heterodimers for molecular imaging. Amino Acids 2011, 41(5):1081-1092.
30. 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids 2011, 41(2):439-447.
31. Maeding P., Fuechtner F., Wuest F. Module-assisted synthesis of the bifunctional labelling agent N-succinimidyl 4-[(18)F]fluorobenzoate ([(18)F]SFB). Appl Radiat Isot 2005, 63:329-332.
32. Fani M., Maecke H.R. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging 2012, 39(Suppl 1):S11-S30.
33. Parry J.J., Andrews R., Rogers B.E. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat 2007, 101(2):175-183.
34. Lappano R., Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discovery 2011, 10:47-60.
35. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006, 103(44):16436-16441.
36. Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008, 49(2):318-326.
37. Wang X., Fani M., Schulz S., Rivier J., Reubi J.C., Maecke H.R. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging 2012, 39(12):1876-1885.
38. 18F-labeled bombesin analog. J Nucl Med 2012, 53(6):947-952.